Your session is about to expire
← Back to Search
Single dose arm for Overactive Bladder
Study Summary
"This trial aims to determine the best way to prevent urinary tract infections (UTIs) in female patients with overactive bladder or bladder pain syndrome who are treated with onabotulinumtoxinA
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 4 trial • 164 Patients • NCT03287089Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any current opportunities for potential participants to enroll in this trial?
"As per clinicaltrials.gov, this research is actively seeking participants. It was first listed on April 4th, 2024 and most recently revised on April 24th of the same year."
What is the upper limit on the number of participants involved in this medical study?
"Affirmative. The information available on clinicaltrials.gov confirms the ongoing recruitment for participants in this medical trial. Originally listed on April 4th, 2024, and last revised on April 24th, 2024, the study aims to enroll a total of 100 subjects at one designated site."
Has the single-dose treatment been officially authorized by the FDA?
"The safety rating for the single-dose arm has been assessed as 3 by our team at Power, owing to this being a Phase 4 trial denoting official approval of the treatment."
Share this study with friends
Copy Link
Messenger